Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In Vitro Activity of Lefamulin Tested against Streptococcus pneumoniae with Defined Serotypes, Including Multidrug-Resistant Isolates Causing Lower Respiratory Tract Infections in the United States.

Literature DB >> 27161634

In Vitro Activity of Lefamulin Tested against Streptococcus pneumoniae with Defined Serotypes, Including Multidrug-Resistant Isolates Causing Lower Respiratory Tract Infections in the United States.

Rodrigo E Mendes¹, David J Farrell², Robert K Flamm², George H Talbot³, Zrinka Ivezic-Schoenfeld⁴, Susanne Paukner⁴, Helio S Sader².

Abstract

Lefamulin was evaluated against various Streptococcus pneumoniae serotypes that were collected from adults with lower respiratory tract infections. Lefamulin exhibited MIC50 and MIC90 values of 0.12 and 0.25 μg/ml, respectively, against the entire collection (n = 822). Similar results were obtained for lefamulin against each of the most common serotypes as well as against multidrug-resistant isolates and strains that are nonsusceptible to ceftriaxone or erythromycin. These data support the clinical development of lefamulin for the treatment of community-acquired respiratory tract infections.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2016 PMID： 27161634 PMCID： PMC4914675 DOI： 10.1128/AAC.00627-16

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

22 in total

1. Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs).

Authors: Helio S Sader; Susanne Paukner; Zrinka Ivezic-Schoenfeld; Douglas J Biedenbach; Franz J Schmitz; Ronald N Jones
Journal: J Antimicrob Chemother Date: 2012-01-27 Impact factor: 5.790

2. Geographic and temporal trends in antimicrobial nonsusceptibility in Streptococcus pneumoniae in the post-vaccine era in the United States.

Authors: Ruth Link-Gelles; Ann Thomas; Ruth Lynfield; Sue Petit; William Schaffner; Lee Harrison; Monica M Farley; Deborah Aragon; Megin Nicols; Pam Daily Kirley; Shelley Zansky; James Jorgensen; Billie Anne Juni; Delois Jackson; Matthew R Moore; Marc Lipsitch
Journal: J Infect Dis Date: 2013-07-12 Impact factor: 5.226

3. Decreased ceftriaxone susceptibility in emerging (35B and 6C) and persisting (19A) Streptococcus pneumoniae serotypes in the United States, 2011-2012: ceftaroline remains active in vitro among β-lactam agents.

Authors: Rodrigo E Mendes; Donald Biek; Ian A Critchley; David J Farrell; Helio S Sader; Ronald N Jones
Journal: Antimicrob Agents Chemother Date: 2014-05-27 Impact factor: 5.191

4. Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010.

Authors: Susanne Paukner; Helio S Sader; Zrinka Ivezic-Schoenfeld; Ronald N Jones
Journal: Antimicrob Agents Chemother Date: 2013-07-08 Impact factor: 5.191

Review 5. Burden of community-acquired pneumonia in North American adults.

Authors: Thomas M File; Thomas J Marrie
Journal: Postgrad Med Date: 2010-03 Impact factor: 3.840

6. Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States.

Authors: Sandra S Richter; Daniel J Diekema; Kristopher P Heilmann; Cassie L Dohrn; Fathollah Riahi; Gary V Doern
Journal: Antimicrob Agents Chemother Date: 2014-08-18 Impact factor: 5.191

7. Community-acquired pneumonia requiring hospitalization among U.S. children.

Authors: Seema Jain; Derek J Williams; Sandra R Arnold; Krow Ampofo; Anna M Bramley; Carrie Reed; Chris Stockmann; Evan J Anderson; Carlos G Grijalva; Wesley H Self; Yuwei Zhu; Anami Patel; Weston Hymas; James D Chappell; Robert A Kaufman; J Herman Kan; David Dansie; Noel Lenny; David R Hillyard; Lia M Haynes; Min Levine; Stephen Lindstrom; Jonas M Winchell; Jacqueline M Katz; Dean Erdman; Eileen Schneider; Lauri A Hicks; Richard G Wunderink; Kathryn M Edwards; Andrew T Pavia; Jonathan A McCullers; Lyn Finelli
Journal: N Engl J Med Date: 2015-02-26 Impact factor: 91.245

8. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance.

Authors: Matthew R Moore; Ruth Link-Gelles; William Schaffner; Ruth Lynfield; Catherine Lexau; Nancy M Bennett; Susan Petit; Shelley M Zansky; Lee H Harrison; Arthur Reingold; Lisa Miller; Karen Scherzinger; Ann Thomas; Monica M Farley; Elizabeth R Zell; Thomas H Taylor; Tracy Pondo; Loren Rodgers; Lesley McGee; Bernard Beall; James H Jorgensen; Cynthia G Whitney
Journal: Lancet Infect Dis Date: 2015-02-03 Impact factor: 25.071

9. Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections.

Authors: W T Prince; Z Ivezic-Schoenfeld; C Lell; K J Tack; R Novak; F Obermayr; G H Talbot
Journal: Antimicrob Agents Chemother Date: 2013-02-19 Impact factor: 5.191

Review 10. Community-acquired pneumonia.

Authors: Elena Prina; Otavio T Ranzani; Antoni Torres
Journal: Lancet Date: 2015-08-12 Impact factor: 79.321

15 in total

Review 1. Leave it to Lefamulin: A Pleuromutilin Treatment Option in Community-Acquired Bacterial Pneumonia.

Authors: Young Ran Lee; Katy Louise Jacobs
Journal: Drugs Date: 2019-11 Impact factor: 9.546

2. Antibacterial Activity of Lefamulin against Pathogens Most Commonly Causing Community-Acquired Bacterial Pneumonia: SENTRY Antimicrobial Surveillance Program (2015-2016).

Authors: Susanne Paukner; Steven P Gelone; S J Ryan Arends; Robert K Flamm; Helio S Sader
Journal: Antimicrob Agents Chemother Date: 2019-03-27 Impact factor: 5.191

3. Low Prevalence of Gram-Positive Isolates Showing Elevated Lefamulin MIC Results during the SENTRY Surveillance Program for 2015-2016 and Characterization of Resistance Mechanisms.

Authors: Rodrigo E Mendes; Susanne Paukner; Timothy B Doyle; Steven P Gelone; Robert K Flamm; Helio S Sader
Journal: Antimicrob Agents Chemother Date: 2019-03-27 Impact factor: 5.191

4. In Vitro Activities of Lefamulin and Other Antimicrobial Agents against Macrolide-Susceptible and Macrolide-Resistant Mycoplasma pneumoniae from the United States, Europe, and China.

Authors: Ken B Waites; Donna M Crabb; Lynn B Duffy; Jorgen S Jensen; Yang Liu; Susanne Paukner
Journal: Antimicrob Agents Chemother Date: 2017-01-24 Impact factor: 5.191

5. In Vitro Activity of the Novel Pleuromutilin Lefamulin (BC-3781) and Effect of Efflux Pump Inactivation on Multidrug-Resistant and Extensively Drug-Resistant Neisseria gonorrhoeae.

Authors: Susanne Jacobsson; Susanne Paukner; Daniel Golparian; Jörgen S Jensen; Magnus Unemo
Journal: Antimicrob Agents Chemother Date: 2017-10-24 Impact factor: 5.191

6. Molecular Characterization of Predominant Serotypes, Drug Resistance, and Virulence Genes of Streptococcus pneumoniae Isolates From East China.

Authors: Li-Dan Huang; Mei-Juan Yang; Yan-Ying Huang; Ke-Yi Jiang; Jie Yan; Ai-Hua Sun
Journal: Front Microbiol Date: 2022-06-01 Impact factor: 6.064